Business Wire

Medicortex Finland Oy Announces Issuance of a Patent for Brain Injury Biomarker

Share

Medicortex Finland Oy, an innovative biopharmaceutical company focused on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that the European Patent Office (EPO) has issued a patent covering company’s new diagnostic kit technology.

“We are extremely pleased with the growth of the patent portfolio related to the TBI testing. This new issuance continues to expand the intellectual property portfolio covering methods to be used for detection of concussion biomarkers. The issuance of this patent is another step in the development of a robust patent portfolio relating to a new strategy to help identify mild TBI” said Dr. Harel Adrian, Chief Executive Officer of Medicortex.

Medicortex is currently developing a rapid diagnostic kit for detection of concussion and mild traumatic brain injury from urine or saliva. The kit is based on specific biomarkers that the company has discovered from body fluids following brain injury. Such a rapid test will fulfill the urgent need to improve the detection of brain injury especially in mild cases – which are potentially harmful but admittedly difficult to diagnose with the contemporary means. The issued patent covers the core technology and method of utilizing glycan-based biomarkers for detection of mild traumatic brain injury, which is presently the company’s main development program.

Medicortex’s patent portfolio comprises of biomarkers for brain injury diagnostics and drug candidates for halting the progression of brain injury. All innovations have been developed by the company. The comprehensive patent coverage secures exclusivity to develop the products, and the company’s strategy is to actively seek new patentable innovations from its biomarker and drug development programs.

About Medicortex

Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence of a head injury. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. Medicortex was established by an Israeli neurobiologist Adrian Harel (Ph.D., MBA) in 2014, and the company is based in Turku, Finland.

Key words: brain injury, head injury, concussion, diagnostics, TBI, early detection, trauma, clinical trial, new patent

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Medicortex assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact information

Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817
adrian.harel@medicortex.fi
http://www.medicortex.fi

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Berkshire Hathaway Specialty Insurance Names Tom Macfarlane to Lead Downstream Energy Property Business in Europe1.12.2020 11:00:00 CETPress release

Berkshire Hathaway Specialty Insurance (BHSI) today announced that it is expanding its capabilities in Europe to underwrite Downstream Energy Property Insurance and has named Tom Macfarlane to lead this business segment. “We are delighted that Tom is joining BHSI to develop our Downstream Energy business in Europe. He is a well-respected leader in the market and has a wealth of experience in the energy sector,” said Chris Colahan, Head of UK and Europe, BHSI. “This is a significant step in continued build-out of our overall Property business. With Tom and his extensive expertise and knowledge at the helm, we look forward to building strong relationships with our customers and brokers in the energy sector,” said Sean Mannion, UK Head of Property, BHSI. Tom comes to BHSI with over 40 years of insurance experience spanning both the underwriting and broking sides of the business. He has held various leadership roles in Energy Property at AIG, including Global Head of Energy. He was also pr

Cobase and Ebury partner on FX services1.12.2020 10:00:00 CETPress release

Leading European fintechs Cobase and Ebury today announce a partnership which opens up Ebury’s FX services to the Cobase multi-banking platform. Cobase, an innovative leader in cloud-based corporate multi-banking solutions, will offer its corporate treasury clients services from Ebury, a leading global FinTech backed by Santander Bank that specializes in cross-border financial services and risk management. The partnership follows the launch of Cobase’s new Liquidity Forecasting and FX Exposure Management modules, which enable corporate treasuries to optimize cash positions or automatically hedge their FX risk on a continuous basis. Adding Ebury’s services to Cobase’s platform will give clients broader access to more cost-effective FX services, and Cobase users will be able to receive competitive FX quotes from Ebury and book FX trades without the need to access any other system. Users will also be able to receive real-time status of transactions and reporting to automate the reconcilia

Henley & Partners: Covid-19 Accelerates Growth of Investment Migration Industry1.12.2020 10:00:00 CETPress release

There has been a 25% increase in the number of HNWIs enquiring about citizenship-by-investment as opposed to residence-by-investment programs since the coronavirus was first reported nearly a year ago, indicating that wealthy international investors are considering a more permanent change. Leading residence and citizenship advisory firm Henley & Partners has also reported an unprecedented and sustained surge in enquiries from citizens of highly developed countries such as Canada, the UK, and the US compared to last year, along with noticeable shifts in its clientele’s priorities. Henley & Partners CEO Dr. Juerg Steffen says that when combined with over a decade of growth in engagement from the buy and sell side, it’s fair to state that investment migration is now very much a mainstream (U)HNWI advisory service. “The value to both investors and their families, and sovereign states and their citizens, is very clear. The volume has also now reached a critical mass where it is reasonable t

Sleep Cycle samarbetar med Petit BamBou för global avslappning1.12.2020 10:00:00 CETPressmeddelande

Sleep Cycle, värdens populäraste intelligenta väckarklocksapp som analyserar användarnas sömn, meddelar idag sitt första partnerskap med en av världens ledande meditationsappar, Petit BamBou för att tillhanda sina globala användare avslappningsinnehåll för en bättre sömn under dessa osäkra tider. Sleep Cycle kommer att visa meditationsinnehåll från Petit BamBou i sitt program Sleep Aid, som innehåller en rad ljudproduktioner som hjälper användaren att somna. Innehållet erbjuder användarna en förbättrad sänggångsrutin som hjälper dem att slappna av och stressa ner innan de går och lägger sig, vilket förbättrar nattsömnen. ”Sömn är lika viktigt för fysisk hälsa som det är för psykets välmående. Att införa en sömnrutin som används inom meditation kan bidra till en stabilare sömn”, berättar Andreas Roman, innehållschef på Sleep Cycle. ”Genom att lägga till Petit Bambous meditationsspår i vårt bibliotek av kurativt innehåll hjälper vi användare att göra meditation till en del av sin vardag

iRhythm Technologies Receives Positive National Guidance in First of its Kind Digital Health Pilot with National Institute for Health and Care Excellence1.12.2020 09:30:00 CETPress release

iRhythm Technologies (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced it is the first technology to pass through a new digital health tech pilot, resulting in a successful recommendation for adoption from the National Institute for Health and Care Excellence (NICE). iRhythm’s Zio XT Service – a patient-friendly ambulatory cardiac monitor supported by deep learning algorithms – has been assessed as part of NICE’s first pilot project to evaluate digital health technologies. Zio XT has been positively recommended by NICE as an option for people with suspected cardiac arrhythmias who would benefit from ECG monitoring for longer than 24 hours. Published today, the guidance concluded that Zio XT is convenient and easy to wear, with greater patient compliance and improved diagnostic yield (a measure of how many people with cardiac arrhythmias are diagnosed) compared with standard 24-hour Holter monitoring. Clinical evi

ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with ‘HIV in View’ - a first-of-its-kind online HIV photography gallery1.12.2020 09:12:00 CETPress release

ViiV Healthcare and Shutterstock Studios today announced the launch of a new online photo gallery ‘HIV in View’,produced by Shutterstock in collaboration with ViiV Healthcare. The collection, curated with the support of people living with HIV, leverages Shutterstock’s global network of over one million creators to deliver a repository of high-resolution images depicting what it means to live with HIV today. Across four countries (the United Kingdom, Kenya, Uruguay, Portugal), people living with HIV stepped forward to be among the first photographed for this gallery, embarking on a shared ambition to help shift the world’s perception of HIV and move away from outdated stereotypes. From World AIDS Day 2020, the gallery will be free for all to access and use in projects, campaigns and communications* in the hope that it will increase awareness around HIV and break down barriers to stigma that still exist. This press release features multimedia. View the full release here: https://www.busi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom